021-51111890
购物车（）
sales@molnova.cn
Danirixin
CAS No. 954126-98-8
Danirixin ( GSK-1325756 )
产品货号. M16816 CAS No. 954126-98-8
Danirixin (GSK-1325756) 是一种高亲和力、选择性和可逆的 CXCR2 拮抗剂 (IC50=12.5 nM, CXCL8)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1102 | 有现货 |
|
| 10MG | ￥1786 | 有现货 |
|
| 25MG | ￥3004 | 有现货 |
|
| 50MG | ￥4297 | 有现货 |
|
| 100MG | ￥5823 | 有现货 |
|
| 200MG | ￥7848 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1064 | 有现货 |
|
生物学信息
-
产品名称Danirixin
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Danirixin (GSK-1325756) 是一种高亲和力、选择性和可逆的 CXCR2 拮抗剂 (IC50=12.5 nM, CXCL8)。
-
产品描述Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8); blocks the CD11b upregulation with pIC50 of 6.05 and 6.3, respectively, in rat and human whole-blood studies; blocks the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide (ED50=1.4 mg/kg); orally active.COPD Phase 2 Clinical(In Vitro):Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
-
体外实验Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
-
体内实验——
-
同义词GSK-1325756
-
通路GPCR/G Protein
-
靶点Chemokine Receptor
-
受体CXCL8-CXCR2
-
研究领域Inflammation/Immunology
-
适应症COPD
化学信息
-
CAS Number954126-98-8
-
分子量441.9041
-
分子式C19H21ClFN3O4S
-
纯度>98% (HPLC)
-
溶解度DMSO: 8 mg/mL
-
SMILESClC(C(S([C@H]1CCCNC1)(=O)=O)=C2O)=CC=C2NC(NC3=CC=CC(F)=C3C)=O
-
化学全称Urea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bloomer JC, et al. Eur J Pharm Biopharm. 2017 Apr 3. pii: S0939-6411(16)31009-8.
2. Miller BE, et al. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.
3. Busch-Petersen J, et al. J Pharmacol Exp Ther. 2017 Aug;362(2):338-346.
